SJ6986, discovered in the thalidomide analog library, is a potent, selective, and orally bioavailable GSPT1/2 degrader targeting patient‐derived leukemia and medulloblastoma cell lines, while degrading IKZF1/3, with clinical development potential.[131, 132] SJ6986 effectively reduced the proliferation of DLBCL cells, induced cell apoptosis, and inhibited tumor growth in vivo without significant toxicity. This evidence concerns the gene GSPT1 and leukemia.